Table 1.
Baseline characteristics and response to neoadjuvant chemotherapy
| Characteristics | Number (%) |
|---|---|
| Age (y) | |
| ≤50 | 64 (58.7) |
| >50 | 45 (41.3) |
| Menopause | |
| Premenopausal | 71 (65.1) |
| Postmenopausal | 38 (34.9) |
| Histology | |
| Invasive ductal carcinoma(IDC) | 105 (96.3) |
| Others | 4 (3.7) |
| Grade | |
| I/II | 90 (82.6) |
| III | 19 (17.4) |
| HR | |
| Positive | 76 (69.7) |
| Negative | 33 (30.3) |
| HER2 | |
| Positive | 30 (27.5) |
| Negative | 79 (72.5) |
| Subtypes | |
| HR+/HER2− | 57 (52.3) |
| HER2+ | 30 (27.5) |
| TNBC | 22 (20.2) |
| Clinical tumor staging | |
| cT1/2 | 60 (55.0) |
| cT3/4 | 49 (45.0) |
| Clinical node staging | |
| cN0 | 10 (9.2) |
| cN1 | 28 (25.7) |
| cN2 | 45 (41.3) |
| cN3 | 26 (23.8) |
| Clinical TNM staging | |
| II | 24 (22.0) |
| III | 85 (78.0) |
| Pathological response | |
| pCR | 10 (9.2) |
| Non‐pCR | 99 (90.8) |
| Objective response | |
| CR/PR | 75 (68.8) |
| SD/PD | 34 (31.2) |